ABBV
Price
$191.08
Change
-$1.34 (-0.70%)
Updated
Jun 13 closing price
Capitalization
322.43B
40 days until earnings call
ALPMY
Price
$9.63
Change
-$0.16 (-1.63%)
Updated
Jun 13 closing price
Capitalization
26.55B
45 days until earnings call
Interact to see
Advertisement

ABBV vs ALPMY

Header iconABBV vs ALPMY Comparison
Open Charts ABBV vs ALPMYBanner chart's image
ABBVIE
Price$191.08
Change-$1.34 (-0.70%)
Volume$4.97M
Capitalization322.43B
Astellas Pharma
Price$9.63
Change-$0.16 (-1.63%)
Volume$81.8K
Capitalization26.55B
ABBV vs ALPMY Comparison Chart
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. ALPMY commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and ALPMY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (ABBV: $191.08 vs. ALPMY: $9.63)
Brand notoriety: ABBV: Notable vs. ALPMY: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 68% vs. ALPMY: 42%
Market capitalization -- ABBV: $322.43B vs. ALPMY: $26.55B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. ALPMY’s [@Pharmaceuticals: Major] market capitalization is $26.55B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 3 FA rating(s) are green whileALPMY’s FA Score has 1 green FA rating(s).

  • ABBV’s FA Score: 3 green, 2 red.
  • ALPMY’s FA Score: 1 green, 4 red.
According to our system of comparison, ABBV is a better buy in the long-term than ALPMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 6 TA indicator(s) are bullish while ALPMY’s TA Score has 7 bullish TA indicator(s).

  • ABBV’s TA Score: 6 bullish, 3 bearish.
  • ALPMY’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, both ABBV and ALPMY are a good buy in the short-term.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +0.66% price change this week, while ALPMY (@Pharmaceuticals: Major) price change was -0.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.36%. For the same industry, the average monthly price growth was +10.48%, and the average quarterly price growth was +8.86%.

Reported Earning Dates

ABBV is expected to report earnings on Jul 25, 2025.

ALPMY is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.36% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($322B) has a higher market cap than ALPMY($26.6B). ABBV has higher P/E ratio than ALPMY: ABBV (66.46) vs ALPMY (37.59). ABBV YTD gains are higher at: 9.547 vs. ALPMY (-0.311). ALPMY has higher annual earnings (EBITDA): 247B vs. ABBV (17.2B). ALPMY has more cash in the bank: 397B vs. ABBV (12.8B). ALPMY has less debt than ABBV: ALPMY (30B) vs ABBV (59.4B). ALPMY has higher revenues than ABBV: ALPMY (1.52T) vs ABBV (54.3B).
ABBVALPMYABBV / ALPMY
Capitalization322B26.6B1,211%
EBITDA17.2B247B7%
Gain YTD9.547-0.311-3,074%
P/E Ratio66.4637.59177%
Revenue54.3B1.52T4%
Total Cash12.8B397B3%
Total Debt59.4B30B198%
FUNDAMENTALS RATINGS
ABBV vs ALPMY: Fundamental Ratings
ABBV
ALPMY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
11100
SMR RATING
1..100
14100
PRICE GROWTH RATING
1..100
4955
P/E GROWTH RATING
1..100
1398
SEASONALITY SCORE
1..100
46n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALPMY's Valuation (4) in the null industry is significantly better than the same rating for ABBV (83) in the Pharmaceuticals Major industry. This means that ALPMY’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for ALPMY (100) in the null industry. This means that ABBV’s stock grew significantly faster than ALPMY’s over the last 12 months.

ABBV's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for ALPMY (100) in the null industry. This means that ABBV’s stock grew significantly faster than ALPMY’s over the last 12 months.

ABBV's Price Growth Rating (49) in the Pharmaceuticals Major industry is in the same range as ALPMY (55) in the null industry. This means that ABBV’s stock grew similarly to ALPMY’s over the last 12 months.

ABBV's P/E Growth Rating (13) in the Pharmaceuticals Major industry is significantly better than the same rating for ALPMY (98) in the null industry. This means that ABBV’s stock grew significantly faster than ALPMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVALPMY
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
41%
Bullish Trend 3 days ago
59%
Momentum
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
66%
MACD
ODDS (%)
Bullish Trend 3 days ago
73%
Bearish Trend 3 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
56%
Bearish Trend 3 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
58%
Bullish Trend 3 days ago
58%
Advances
ODDS (%)
Bullish Trend 4 days ago
56%
Bullish Trend 4 days ago
62%
Declines
ODDS (%)
Bearish Trend 26 days ago
46%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
65%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
43%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RNMBY414.0010.10
+2.50%
Rheinmetall AG
WJRYY22.030.10
+0.46%
West Japan Railway Co.
AYASF9.700.02
+0.23%
Aya Gold & Silver Inc.
CLLNY19.02-0.10
-0.54%
Cellnex Telecom SA
PVCT0.07N/A
-3.43%
Provectus Biopharmaceuticals, Inc.

ABBV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABBV
1D Price
Change %
ABBV100%
-0.70%
PFE - ABBV
55%
Loosely correlated
-1.21%
AMGN - ABBV
49%
Loosely correlated
-0.70%
NVS - ABBV
45%
Loosely correlated
-1.09%
JNJ - ABBV
44%
Loosely correlated
+0.28%
GILD - ABBV
41%
Loosely correlated
-1.15%
More

ALPMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPMY has been loosely correlated with ALPMF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPMY jumps, then ALPMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPMY
1D Price
Change %
ALPMY100%
-1.63%
ALPMF - ALPMY
37%
Loosely correlated
N/A
OPHLY - ALPMY
32%
Poorly correlated
-1.65%
OTSKY - ALPMY
21%
Poorly correlated
-1.29%
BAYRY - ALPMY
13%
Poorly correlated
-1.99%
ABBV - ALPMY
12%
Poorly correlated
-0.70%
More